Blog - Page 4084 of 5386

MondayNov 03, 2008 3:52 am

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company's web site at www.accentia.net.

SundayNov 02, 2008 9:10 am

Adherex Technologies, Inc. (AMEX: ADH)

Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company's web site at www.adherex.com.

SundayNov 02, 2008 9:09 am

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access' products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company's web site at www.accesspharma.com.

SundayNov 02, 2008 9:09 am

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

SundayNov 02, 2008 9:08 am

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company, is focused on utilizing innovative technology to stimulate drug discovery and clinical development of novel treatments for central nervous system disorders. The company is currently developing a portfolio of its four most advanced product candidates, all of which originate from discoveries made using ACADIA’s proprietary drug discovery platform. For further information, visit the Company's web site at www.acadia-pharm.com.

SundayNov 02, 2008 9:04 am

Aastrom Biosciences, Inc. (NASDAQ: ASTM)

Aastrom Biosciences, Inc. (NASDAQ: ASTM) is focused on the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology utilizes a patient's own cells to create products to treat an array of chronic diseases as well as serious injuries. Currently, Aastrom is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial). For further information, visit the Company's web site at www.aastrom.com.

SundayNov 02, 2008 9:03 am

A.P. Pharma, Inc. (NASDAQ: APPA)

A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, is committed to developing ethical (prescription) pharmaceuticals through the utilization of its proprietary polymer-based drug delivery systems. The Company's main focus is on developing and commercializing its bioerodible injectable and implantable systems under the trade name Biochronomer™. For further information, visit the Company's web site at www.appharma.com.

SundayNov 02, 2008 5:06 am

Kona Grill, Inc. (KONA) Announces Third Quarter Financial Results; CEO Comments on Fourth Quarter and Year-End Outlook

Kona Grill, Inc. (NASD: KONA), an American grill and sushi bar, recently announced its financial results for the third quarter ended September 30, 2008. Restaurant sales from continuing operations increased 4.3 percent to $19.5 million from $18.7 million during the corresponding quarter in 2007. The increase in restaurant sales during the third quarter reflects additional revenue from three stores opened since November 2007. The company expects fourth quarter sales to range between $19.3 million to $19.8 million with a net loss from continuing operations of $1.2 million to $1.5 million, or a net loss of $0.18 to $0.23 per diluted…

SundayNov 02, 2008 5:04 am

Provectus Pharmaceuticals, Inc. (PVCT.OB) Introduces New Center as Phase 2 Begins for Leading Oncology Agent

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) announced that they have commenced recruitment for their Phase 2 clinical trial of the company's lead oncology agent PV-10 at a fifth major center, now covering the northeastern United States. The new center joins the other company's centers located in Sydney, Brisbane and Adelaide, Australia, and Houston, Texas. Sanjiv Agarwala, M.D. has been appointed as the principal investigator at the new center, located at St. Luke's Hospital & Health Network, in Bethlehem, PA. Over the next several months, the company intends to continue expansion of the study to include sites in other major population…

FridayOct 31, 2008 12:43 pm

Wall Street Ends Worst Month in 21 Years on High Note

As the closing bell rang on Friday, it marked the end of the worst month that the stock market has seen since 1987. For investors, October 2008 is not a month that will be looked upon with great nostalgia in years to come, however, despite the release of a report that reflected the fears of hesitant consumers, indices rose significantly. The Dow Jones closed at 9,325; up 144 points or 1.57 percent on the day. Let us hear your thoughts below:

Site Search

Company Search

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

Adherex Technologies, Inc. (AMEX: ADH)

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)

Aastrom Biosciences, Inc. (NASDAQ: ASTM)

A.P. Pharma, Inc. (NASDAQ: APPA)

Kona Grill, Inc. (KONA) Announces Third Quarter Financial Results; CEO Comments on Fourth Quarter and Year-End Outlook

Provectus Pharmaceuticals, Inc. (PVCT.OB) Introduces New Center as Phase 2 Begins for Leading Oncology Agent

Wall Street Ends Worst Month in 21 Years on High Note

Market Basics

Newsletter Publishers

Public Companies